These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2005-005794-29 Traitement des syndromes myélodysplasiques par l'association aracytine et bortezomib not-yet-due
Ongoing 2007-000246-13 A phase II study of the efficacity and the safety of lenalidomide in subjects with intermediate or the high risk myelodysplastic syndromes (MSD) associated with a deletion (Del) 5q[31] not-yet-due
Exempt 2007-002212-26 A Phase I/II Study of Vorinostat in Combination with Low Dose Ara-C for Patients with Intermediate-2 or High Risk Myelodysplastic Syndromes not-yet-due
Ongoing 2008-000470-21 A Phase II study of Decitabine in patients with Chronic Myelomonocytic Leukemia not-yet-due
Completed, but no date 2008-004541-29 A phase II Study of Azacitidine (Vidaza®) combined to Epoetin beta (NeoRecormon®) in IPSS low-risk and intermediate-1 MDS Patients, resistant to ESA bad-data
Exempt 2008-005999-28 PHASE I-II TRIAL OF ERLOTINIB IN HIGHER RISK MYELODYSPLASTIC SYNDROME not-yet-due
Completed, but no date 2008-006032-36 A phase ii study of the efficacy and safety of lenalidomide combined to escalating doses of chemotherapy in intermediate-2-or high risk MDS and AML with del 5 q31 bad-data
Completed, but no date 2008-008262-12 A phase II study evaluating the efficacy and safety of Lenalidomide (Revlimid®) with or without Epoetin beta (NeoRecormon®) in transfusion-dependent ESA-resistant patients with IPSS low- and intermedi... bad-data
Not reported 2009-011160-11 A phase II study of the efficacy and safety of lenalidomide combined to azacitidine in intermediate-2 or high risk MDS AND AML with del 5q 2016-07-25 due-trials
Ongoing 2009-011161-87 Treatment of anemia in myelodysplastic syndromes low risk with epoetin beta with Analysis of impact on quality of life and functional capacity not-yet-due
Exempt 2009-013404-32 A Phase I/II Multicenter Study of IV Clofarabine In Patients with High-Risk Myelodysplastic Syndrome who have failed Therapy with Azacitidine: the NIDEVOL study not-yet-due
Exempt 2009-017178-19 A phase I-II study of the efficacy and safety of Idarubicin combined to Azacitidine in int-2 or high risk myelodysplastic syndromes 2016-05-09 not-yet-due
Exempt 2010-019709-41 A phase I study of azacitidine with Ceplene/interleukin-2 followed by a randomized phase II study of the efficacy and safety of maintenance treatment with azacitidine with or without Ceplene/interleuk... not-yet-due
Exempt 2010-020341-27 A phase I/II study of the efficacy and safety of an intensified schedule of Azacitidine (Vidaza®) in intermediate-2 and high risk MDS patients not-yet-due
Exempt 2012-003120-21 A phaseI-II trial of acadesine in ipss high and int 2 myelodysplastic syndromes, acute myeloid leukemia with 20-30% marrow blasts and chronic myelomonocytic leukemia type 2 not responding to azacitidi... not-yet-due
Not reported 2014-000098-38 A phase II trial of SGI-110 in patients with ipss high and int 2 myelodysplastic syndrome, acute myeloid leukemia with 20-30% marrow blasts and chronic myelomonocytic leukemia type 2 not responding to... 2018-04-23 due-trials
Ongoing 2014-000200-10 A Randomized Phase III study of Decitabine (DAC) with or without Hydroxyurea (HY) versus HY in patients with advanced proliferative Chronic Myelomonocytic Leukemia (CMML) not-yet-due
Ongoing 2017-003681-27 A single-arm phase II multicenter study of IDH1 (AG 120) inhibitor in patients with IDH1 mutated myelodysplastic syndrome not-yet-due